

Long-Acting Injectables (LAIs) Market Report Highlights Key Segments, Regional Trends And Major Competitors

The Business Research Company's Long-Acting Injectables (LAIs) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, July 17, 2026

/EINPresswire.com/ -- The long-acting injectables (LAIs) market has witnessed

significant expansion in recent years, capturing attention due to its potential to improve patient outcomes and medication adherence. As demand for innovative drug delivery solutions rises, the market is expected to continue its upward trajectory, driven by both medical needs and technological advancements.

Growth and Market Size [Overview for Long-Acting Injectables \(LAIs\)](#)

The LAIs market has experienced rapid growth and is projected to increase from \$13.31 billion in 2025 to \$15.01 billion in 2026, reflecting a healthy compound annual growth rate (CAGR) of 12.7%. This historical growth has been fueled by factors such as the rising prevalence of schizophrenia and bipolar disorder, increased demand for better medication adherence, early innovations in depot injection technologies, wider use of hormonal injectable contraceptives, and a limited number of sustained-release drug delivery options. Looking ahead, the market is expected to reach \$24.45 billion by 2030, growing at a CAGR of 13.0%. This projected growth is driven by advancements in nano- and polymer-based drug delivery technologies, growing approvals for long-acting antiviral medications, greater adoption of precision medicine, expansion of homecare and outpatient treatment models, and increased investment in extended-release injectable drug pipelines. Emerging trends include greater use of LAIs to manage chronic psychiatric conditions, wider deployment of depot formulations to enhance patient compliance and reduce dosing frequency, development of sophisticated polymer and nano delivery systems for sustained release, expanding clinical use of long-acting antivirals for infectious diseases, and integration of LAIs within outpatient and specialty clinics.

Download a free sample of the [long-acting injectables \(lais\) market report](#):

https://www.thebusinessresearchcompany.com/sample_request?id=33392612&type=smp&nam

The Business
Research Company

The Business Research Company



[e=Long-](#)

[Acting%20Injectables%20%28LAIs%29%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR](#)

Understanding Long-Acting Injectables (LAIs) and Their Role

Long-acting injectables refer to a category of medicines designed to steadily release active compounds into the body over an extended timeframe following a single injection. This approach maintains consistent drug levels in the bloodstream for weeks or months, minimizing the need for frequent dosing compared to traditional oral medications or shorter-acting injectables. This delivery system offers significant benefits in terms of patient convenience and medication adherence, particularly for chronic conditions requiring ongoing treatment.

Impact of Schizophrenia on the Long-Acting Injectables (LAIs) Market Growth

One of the major factors contributing to the expansion of the LAIs market is the growing burden of schizophrenia, a chronic mental health disorder that disrupts thinking, emotions, and behavior, often manifesting as hallucinations, delusions, and disorganized thought processes. Increased awareness surrounding mental health has led to higher diagnosis rates and more individuals seeking treatment. Long-acting injectables are valuable in managing schizophrenia because they provide consistent medication delivery over time, reducing relapse rates and supporting improved symptom control. For example, in January 2026, WebMD LLC reported that schizophrenia caused an economic burden of nearly \$367 billion in the United States in 2024, affecting approximately 3.1 million adults. This significant impact underscores why rising schizophrenia prevalence is propelling demand for LAIs.

View the full long-acting injectables (LAIs) market report:

[\[https://www.thebusinessresearchcompany.com/report/long-acting-injectables-lais-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR\]\(https://www.thebusinessresearchcompany.com/report/long-acting-injectables-lais-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jul_PR\)](#)

Regional Dynamics Shaping the Long-Acting Injectables (LAIs) Market

In 2025, North America held the largest share of the long-acting injectables market, underlining its established healthcare infrastructure and strong adoption of innovative therapies. Meanwhile, the Asia-Pacific region is anticipated to be the fastest-growing market over the forecast period, driven by increasing healthcare investments, growing awareness of mental health issues, and expanding access to advanced treatments. The comprehensive market analysis includes regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a global perspective on market trends and growth opportunities.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Learn More About [The Business Research Company](#)

With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at marketing@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/927462051>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.